āϏ⧋āϏāĻžāχāϟāĻŋ āĻ—āĻžāχāĻĄ

FDA Predetermined Change Control Plans for AI Devices

An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed.

āĻāχ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāĻ•āĻž āĻļ⧁āύ⧁āύāĻāφāχ-āĻŦāĻ°ā§āĻŖāĻŋāϤ ¡ ~3 min

āĻāχ āĻĒ⧃āĻˇā§āĻ āĻžāϝāĻŧ3 āĻŽāĻŋāύāĻŋāϟ āĻĒāĻĄāĻŧāĻž āĻšāϝāĻŧ⧇āϛ⧇
  1. āĻ“āĻ­āĻžāϰāĻ­āĻŋāω
  2. āĻ—āĻ­ā§€āϰ āĻĄā§āĻŦ
  3. āĻŦāĻžāĻ¸ā§āϤāĻŦ-āĻŦāĻŋāĻļā§āĻŦ āĻŦāĻžāĻ¸ā§āϤāĻŦāĻžāϝāĻŧāύ
  4. The Future of FDA Predetermined Change Control Plans for AI Devices
  5. āĻāϟāĻžāϕ⧇ āĻŦāĻžāĻ¸ā§āϤāĻŦ⧇ āĻĒā§āϰāϝāĻŧā§‹āĻ— āĻ•āϰāĻž āĻšāĻšā§āϛ⧇
  6. āĻ…āĻ¨ā§āĻŦ⧇āώāĻŖ āϚāĻžāϞāĻŋāϝāĻŧ⧇ āϝāĻžāύ
  7. āĻĒā§āϰāĻžāϝāĻŧāĻļāχ āϜāĻŋāĻœā§āĻžāĻžāϏāĻŋāϤ āĻĒā§āϰāĻļā§āύāĻžāĻŦāϞ⧀

āĻ“āĻ­āĻžāϰāĻ­āĻŋāω

FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.

āĻ—āĻ­ā§€āϰ āĻĄā§āĻŦ

A PCCP is a planned change-management component of a medical-device marketing submission. FDA’s August 2025 final guidance gives recommendations for PCCPs tailored to AI-enabled device software functions, including the device constituent part of device-led combination products reviewed through 510(k), De Novo, and PMA pathways. FDA reviews the proposed plan with the marketing submission to assess whether the described changes can be made while maintaining a reasonable assurance of safety and effectiveness. A PCCP does not permit unrestricted changes. The guidance organizes the plan around three elements: a description of planned modifications, a modification protocol for developing, validating, and implementing those changes, and an impact assessment addressing benefits and risks. The planned changes need defined boundaries. The protocol should state methods, acceptance criteria, data controls, validation, implementation safeguards, and monitoring appropriate to the device and proposed change. The impact assessment should explain how changes could affect safety and effectiveness, including interactions among modifications. Vague promises to “retrain as needed” do not provide a meaningful boundary or evidence plan. After FDA authorizes a PCCP, a manufacturer may implement modifications that conform to the authorized plan without a new marketing submission for each described modification. It must still follow applicable quality-system, labeling, reporting, and other regulatory obligations. A proposed change outside the PCCP, or one that fails its protocol, requires a separate regulatory assessment. Depending on the change and device pathway, a new 510(k), De Novo, PMA supplement, or other action may be required. PCCP authorization therefore changes the route for a bounded category of updates; it does not exempt a product from device regulation. The 2025 guidance is final agency guidance and expresses FDA’s current recommendations; guidance does not itself establish legally enforceable responsibilities unless specific statutory or regulatory requirements apply. Manufacturers should distinguish this AI-focused guidance from earlier draft documents and from joint international PCCP guiding principles. Align scope, evidence, risk controls, and monitoring with the device and patient context.

āĻŦāĻžāĻ¸ā§āϤāĻŦ-āĻŦāĻŋāĻļā§āĻŦ āĻŦāĻžāĻ¸ā§āϤāĻŦāĻžāϝāĻŧāύ

A radiology software maker proposes a bounded retraining method, validation protocol, and performance limits for a device intended to detect a defined finding.

A manufacturer specifies which input hardware can be added and how each configuration will be tested before release.

A change to a model’s intended population falls outside the authorized PCCP, so the manufacturer evaluates whether a new marketing submission is required.

A quality team links each released model update to the authorized plan, validation evidence, risk review, and post-market monitoring record.

The Future of FDA Predetermined Change Control Plans for AI Devices

FDA’s guidance supports iterative improvement under defined controls while retaining review of safety and effectiveness. As experience accumulates, agency recommendations, standards, and accepted evidence methods may evolve. Manufacturers should check the current FDA guidance and submission requirements when preparing a plan, and reassess when the device, intended population, or update method changes. A successful PCCP depends on evidence and operational controls after clearance as well as the initial submission. Schedule a review when FDA revises the guidance or the device’s update method changes.

āĻāϟāĻžāϕ⧇ āĻŦāĻžāĻ¸ā§āϤāĻŦ⧇ āĻĒā§āϰāϝāĻŧā§‹āĻ— āĻ•āϰāĻž āĻšāĻšā§āϛ⧇

āϕ⧇āύ āĻāϟāĻž āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ

  • āĻā§āρāĻ•āĻŋ āĻāĻŦāĻ‚ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž. āĻŦāĻŋāĻĒāĻ°ā§āϝāϝāĻŧāĻ•āϰ āĻāĻŦāĻ‚ āĻĻ⧈āύāĻ¨ā§āĻĻāĻŋāύ āĻāφāχ āĻ•ā§āώāϤāĻŋ āωāĻ­āϝāĻŧāχ āύāĻŋāĻ°ā§āĻ­āϰ āĻ•āϰ⧇ āϕ⧇ āĻā§āρāĻ•āĻŋ āĻŦ⧁āĻāϤ⧇ āĻĒāĻžāϰ⧇ āĻāĻŦāĻ‚ āϕ⧇ āĻ•āĻžāϜ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  • āϏ⧁āĻ¸ā§āĻĒāĻˇā§āϟ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ. āϜāύāϏāĻžāϧāĻžāϰāϪ⧇āϰ āĻāĻŦāĻ‚ āĻĒ⧇āĻļāĻžāĻĻāĻžāϰ āϏāĻžāĻ•ā§āώāϰāϤāĻž āĻ—āĻ āύ āĻ•āϰ⧇ āϝ⧇ āĻļāĻ•ā§āϤāĻŋāĻļāĻžāϞ⧀ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āύ⧀āϤāĻŋ āϰāĻžāϜāύ⧈āϤāĻŋāĻ•āĻ­āĻžāĻŦ⧇ āϏāĻŽā§āĻ­āĻŦ āĻ•āĻŋāύāĻžāĨ¤
  • āĻšāĻžāχāĻĒ⧇āϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻ•āĻžāϟāĻž. āĻ¸ā§āĻĒāĻˇā§āϟ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž āĻšāĻžāχāĻĒ, āĻ˛ā§āϝāĻžāĻŦ āĻĒāĻŋāφāϰ, āĻāĻŦāĻ‚ āĻ…āĻ¸ā§āĻĒāĻˇā§āϟ āύ⧀āϤāĻŋāĻļāĻžāĻ¸ā§āĻ¤ā§āϰ āĻĨāĻŋāϝāĻŧ⧇āϟāĻžāϰ āĻĻā§āĻŦāĻžāϰāĻž āĻ•ā§āϝāĻžāĻĒāϚāĻžāϰ āĻšā§āϰāĻžāϏ āĻ•āϰ⧇āĨ¤

āϜāĻ¨ā§āϝ āϏāϤāĻ°ā§āĻ•

  • āϏāĻ•ā§āώāĻŽāϤāĻž āϝ⧌āĻ—āĻŋāĻ• āĻ…āĻŦāĻ¸ā§āĻĨāĻžāϝāĻŧ āĻ…āĻ¸ā§āϤāĻŋāĻ¤ā§āĻŦāĻ—āϤ āĻā§āρāĻ•āĻŋāϕ⧇ āϏāĻžāχ-āĻĢāĻžāχ āĻšāĻŋāϏāĻžāĻŦ⧇ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻžāĨ¤
  • āωāĻšā§āϚ āĻ¸ā§āĻŦāĻžāϝāĻŧāĻ¤ā§āϤāĻļāĻžāϏāύ⧇āϰ āĻ…āϧ⧀āύ⧇ āĻĒā§āϰāĻžāĻ¨ā§āϤāĻŋāĻ•āĻ•āϰāϪ⧇āϰ āϏāĻžāĻĨ⧇ āĻŦāĻŋāĻ­ā§āϰāĻžāĻ¨ā§āϤāĻŋāĻ•āϰ āĻĒ⧃āĻˇā§āĻ  āĻĒāĻŖā§āϝ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻžāĨ¤
  • āĻ…-āχāĻ‚āϰ⧇āϜāĻŋ āĻāĻŦāĻ‚ āĻ…-āĻŦāĻŋāĻļ⧇āώāĻœā§āĻž āĻļā§āϰ⧋āϤāĻžāĻĻ⧇āϰ āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ āύāĻŋāĻŽā§āύ-āĻŽāĻžāύ⧇āϰ āωāĻ¤ā§āϏ āϏāĻš āĻ¤ā§āϝāĻžāĻ— āĻ•āϰāĻžāĨ¤

āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻĒāĻĻāĻ•ā§āώ⧇āĻĒ

  1. āĻĒ⧃āĻĨāĻ• āĻĒāĻŖā§āϝ āĻ•ā§āώāϤāĻŋ, āĻ…āĻĒāĻŦā§āϝāĻŦāĻšāĻžāϰ, āĻāĻŦāĻ‚ āĻ•ā§āώāϤāĻŋ-āĻ…āĻŦ-āύāĻŋāϝāĻŧāĻ¨ā§āĻ¤ā§āϰāĻŖ/āĻŦāĻŋāĻ­ā§āϰāĻžāĻ¨ā§āϤāĻŋāϰ āĻā§āρāĻ•āĻŋāĨ¤
  2. āϜāĻŋāĻœā§āĻžāĻžāϏāĻž āĻ•āϰ⧁āύ āĻ•āĻŋ āĻĒā§āϰāĻŽāĻžāĻŖ āϏāĻŽāϝāĻŧāϏ⧀āĻŽāĻž āĻāĻŦāĻ‚ āϤ⧀āĻŦā§āϰāϤāĻž āφāĻĒāύāĻžāϰ āĻĻ⧃āĻˇā§āϟāĻŋāĻ­āĻ™ā§āĻ—āĻŋ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻ•āϰāĻŦ⧇.
  3. āĻŦāĻŋāĻĒāĻŖāύ āĻĻāĻžāĻŦāĻŋāϰ āĻšā§‡āϝāĻŧ⧇ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ• āωāĻ¤ā§āϏ āĻāĻŦāĻ‚ āĻ•āĻ‚āĻ•ā§āϰāĻŋāϟ āχāĻ­āĻžāϞ āĻĒāĻ›āĻ¨ā§āĻĻ āĻ•āϰ⧁āύāĨ¤
  4. āĻāĻ•āϟāĻŋ āĻ•āĻ°ā§āĻŽ āĻĒāĻĨ āϚāĻŋāĻšā§āύāĻŋāϤ āĻ•āϰ⧁āύ: āĻ•āĻ°ā§āĻŽāĻœā§€āĻŦāύ, āύ⧀āϤāĻŋ, āĻ…āĻ°ā§āĻĨāĻžāϝāĻŧāύ, āĻŦāĻž āĻĻāĻ•ā§āώāϤāĻž - āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ āϏāĻšā§‡āϤāύāϤāĻž āύāϝāĻŧāĨ¤

āĻ…āĻ¨ā§āĻŦ⧇āώāĻŖ āϚāĻžāϞāĻŋāϝāĻŧ⧇ āϝāĻžāύ

āĻĢā§āϰāĻŋ āύāĻŋāωāϜāϞ⧇āϟāĻžāϰ

āĻĒā§āϰāϤāĻŋāĻĻāĻŋāύ⧇āϰ āĻāφāχ āĻŦā§āϰāĻŋāĻĢāĻŋāĻ‚ āĻĒāĻžāύ

āĻĒā§āϰāϤāĻŋ āϏāĻĒā§āϤāĻžāĻšā§‡āϰ āĻ•āĻžāĻœā§‡āϰ āĻĻāĻŋāύ āϏāĻ•āĻžāϞ⧇ āϤāĻŋāύāϟāĻŋ āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ āĻāφāχ āĻ¸ā§āĻŸā§‹āϰāĻŋ, āϏāĻšāϜ āχāĻ‚āϰ⧇āϜāĻŋāϤ⧇ āϞ⧇āĻ–āĻžāĨ¤ āϚāĻŋāϰāĻ•āĻžāϞ⧇āϰ āϜāĻ¨ā§āϝ āĻĢā§āϰāĻŋ, āϕ⧋āύ⧋ āĻŦāĻŋāĻœā§āĻžāĻžāĻĒāύ āύ⧇āχāĨ¤

āĻĒā§āϰāϤāĻŋ āϏāĻĒā§āϤāĻžāĻšā§‡āϰ āĻ•āĻžāĻœā§‡āϰ āĻĻāĻŋāύ⧇ āĻāĻ•āϟāĻŋ āχāĻŽā§‡āϞāĨ¤ āĻāĻ• āĻ•ā§āϞāĻŋāϕ⧇āχ āφāύāϏāĻžāĻŦāĻ¸ā§āĻ•ā§āϰāĻžāχāĻŦ āĻ•āϰ⧁āύāĨ¤ āφāĻŽāϰāĻž āĻ•āĻ–āύ⧋āχ āφāĻĒāύāĻžāϰ āĻ āĻŋāĻ•āĻžāύāĻž āĻŦāĻŋāĻ•ā§āϰāĻŋ āĻŦāĻž āĻļā§‡ā§ŸāĻžāϰ āĻ•āϰāĻŋ āύāĻžāĨ¤

āύāĻŋāĻœā§‡āϕ⧇ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧁āύ

Take the FDA Predetermined Change Control Plans for AI Devices quiz

āĻĒā§āϰāϤāĻŋāϟāĻŋ āωāĻ¤ā§āϤāϰ⧇āϰ āϤāĻžā§ŽāĻ•ā§āώāĻŖāĻŋāĻ• āĻĢāĻŋāĻĄāĻŦā§āϝāĻžāĻ•, āĻāĻŦāĻ‚ āϕ⧋āĻ°ā§āϏ āĻĒāĻžāϏ āĻ•āϰāĻžāϰ āĻĒāϰ āϝāĻžāϚāĻžāχāϝ⧋āĻ—ā§āϝ āφāχāĻĄāĻŋ āϏāĻš āĻāĻ•āϟāĻŋ āĻļā§‡ā§ŸāĻžāϰāϝ⧋āĻ—ā§āϝ āϏāĻžāĻ°ā§āϟāĻŋāĻĢāĻŋāϕ⧇āϟāĨ¤

āϕ⧁āχāϜ āĻļ⧁āϰ⧁ āĻ•āϰ⧁āύ

āĻĢā§āϰāĻŋ āĻāφāχ āĻļāĻŋāĻ•ā§āώāĻžāϕ⧇ āϏāĻŽāĻ°ā§āĻĨāύ āĻ•āϰ⧁āύāĨ¤ AI Understanding āĻāĻ•āϟāĻŋ 501(c)(3) āĻ…āϞāĻžāĻ­āϜāύāĻ• āĻĒā§āϰāϤāĻŋāĻˇā§āĻ āĻžāύ — āϕ⧋āύ⧋ āĻŦāĻŋāĻœā§āĻžāĻžāĻĒāύ āύ⧇āχ, āϕ⧋āύ⧋ āĻĒ⧇āĻ“ā§ŸāĻžāϞ āύ⧇āχ, āĻ•āĻ–āύ⧋āχ āύāĻžāĨ¤ āĻāĻ•āϟāĻŋ āĻĻāĻžāύ āĻ•āϰ⧁āύ

āĻĒā§āϰāĻžāϝāĻŧāĻļāχ āϜāĻŋāĻœā§āĻžāĻžāϏāĻŋāϤ āĻĒā§āϰāĻļā§āύāĻžāĻŦāϞ⧀

What is FDA Predetermined Change Control Plans for AI Devices?

An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed. FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.

Which three elements form the core of an AI-device PCCP?

FDA’s final guidance describes planned modifications, a protocol for implementing them, and an assessment of their impact.

When does FDA review a proposed PCCP?

FDA reviews the PCCP as part of the relevant marketing submission.

What does PCCP authorization allow a manufacturer to do?

The plan can support specified future modifications without a new marketing submission for each change, if they follow the authorized plan.

A manufacturer wants to add a new patient population that its PCCP did not describe. What is the appropriate next step?

A change outside the authorized scope needs a regulatory assessment and may require a new submission.

Which version of FDA’s AI-device PCCP guidance is final?

FDA identifies its tailored final guidance as issued in August 2025.

āĻļāĻŋāĻ–āϤ⧇ āĻĨāĻžāϕ⧁āύ

āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ āĻ—āĻžāχāĻĄ

āĻāχ āĻŦāĻŋāώāϝāĻŧ⧇āϰ āϜāĻ¨ā§āϝ āĻŦāĻžāĻ›āĻžāχ āĻ•āϰāĻž āφāϰāĻ“ āĻ—āĻžāχāĻĄ

āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āφāĻĒāĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻ—āĻžāχāĻĄ

āĻāφāχ āĻŽā§‡āĻĄāĻŋāϕ⧇āϞ āĻĄāĻŋāĻ­āĻžāχāϏ⧇āϰ āĻāĻĢāĻĄāĻŋāĻ āϰ⧇āϗ⧁āϞ⧇āĻļāύ

āĻļāĻŋāĻ˛ā§āĻĒ

āĻāĻ•āϟāĻŋ āĻŦāĻŋāύāĻžāĻŽā§‚āĻ˛ā§āϝ⧇ AI āĻļāĻ‚āϏāĻžāĻĒāĻ¤ā§āϰ āĻĒāĻžāύāĻāĻ•āϟāĻŋ āϏāĻ‚āĻ•ā§āώāĻŋāĻĒā§āϤ āĻŦāĻŋāύāĻžāĻŽā§‚āĻ˛ā§āϝ⧇ āϕ⧋āĻ°ā§āϏ āĻāĻŦāĻ‚ āĻĒāϰ⧀āĻ•ā§āώāĻž. āϕ⧋āύ⧋ āĻ–āϰāϚ āύ⧇āχ, āϕ⧋āύ⧋ āĻ•āĻžāĻ°ā§āĻĄ āύ⧇āχāĨ¤ āĻĒā§āϰāĻžāϝāĻŧ 2.5 āϘāĻ¨ā§āϟāĻžāĨ¤āĻŦāĻŋāύāĻžāĻŽā§‚āĻ˛ā§āϝ⧇ āĻļ⧁āϰ⧁ āĻ•āϰ⧁āύ →